雌激素受体：乳腺癌中的一种稳定表型。
Oestrogen receptor: a stable phenotype in breast cancer.
作者信息
Robertson J F
机构信息
City Hospital, Nottingham, UK.
出版信息
Br J Cancer. 1996 Jan;73(1):5-12. doi: 10.1038/bjc.1996.2.
Abstract
Oestrogen receptor (ER) expression in breast cancer is regarded as a phenotype that may change during the natural history of the disease or during endocrine therapy. It has been suggested that in up to 70% of tumours that show acquired resistance the mechanism may be changed in ER status from positive to negative. This paper proposes an alternative hypothesis that ER expression in a stable phenotype in breast cancer. The paper reviews the literature on ER expression during the natural history of breast cancer in patients and also presents data on the effect of endocrine therapy on ER expression. If the alternative hypothesis is true it has important implications for treatment from chemoprevention to acquired endocrine resistance in advanced disease. Equally, if the hypothesis is true, attempts to develop laboratory models of endocrine resistance where ER-positive tumours become ER negative need to be re-evaluated.
摘要
雌激素受体（ER）在乳腺癌中的表达被视为一种可能在疾病自然史或内分泌治疗过程中发生变化的表型。有人提出，在高达70%显示获得性耐药的肿瘤中，ER状态的机制可能从阳性转变为阴性。本文提出了另一种假说，即ER在乳腺癌中以稳定表型表达。本文回顾了关于乳腺癌患者疾病自然史中ER表达的文献，并展示了内分泌治疗对ER表达影响的数据。如果该替代假说成立，那么从化学预防到晚期疾病的获得性内分泌耐药的治疗都将具有重要意义。同样，如果该假说成立，那么开发ER阳性肿瘤变为ER阴性的内分泌耐药实验室模型的尝试需要重新评估。
相似文献
1
Oestrogen receptor: a stable phenotype in breast cancer.雌激素受体：乳腺癌中的一种稳定表型。
Br J Cancer. 1996 Jan;73(1):5-12. doi: 10.1038/bjc.1996.2.
2
bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.bcl-2在正常人类乳腺及癌组织中的表达，与雌激素受体阳性、表皮生长因子受体阴性肿瘤及原位癌的关系。
Br J Cancer. 1994 Jan;69(1):135-9. doi: 10.1038/bjc.1994.22.
3
Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation.长期雌激素剥夺后T47D乳腺癌细胞中雌激素受体的不可逆丧失。
Br J Cancer. 1996 Oct;74(8):1227-36. doi: 10.1038/bjc.1996.521.
4
High incidence of oestrogen receptor negative progesterone receptor positive phenotype in Indian breast cancer: fact or fiction?印度乳腺癌中雌激素受体阴性孕激素受体阳性表型的高发生率：事实还是虚构？
Indian J Pathol Microbiol. 2005 Apr;48(2):199-201.
5
Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.与第一肿瘤特征、内分泌治疗和放疗相关的对侧乳腺癌的预后、分期和雌激素受体状态。
Eur J Cancer. 2015 Nov;51(16):2304-13. doi: 10.1016/j.ejca.2015.07.016. Epub 2015 Aug 1.
6
Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers?为什么雌激素受体阴性的乳腺癌比雌激素受体阳性的乳腺癌更具侵袭性？
Invasion Metastasis. 1994;14(1-6):329-36.
7
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.乳腺癌内分泌治疗耐药：利用雌激素受体/生长因子信号转导的相互作用
Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S15-24. doi: 10.1677/erc.1.01273.
8
Immunohistochemical analysis of the functional status of estrogen receptor cascade in breast cancer.
Neoplasma. 1998;45(2):83-7.
9
Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.雌激素受体调节剂对雌激素受体（ER）阳性乳腺癌发生率的选择性降低，支持了ER阳性和ER阴性乳腺癌之间的病因学区分。
Med Hypotheses. 2005;64(6):1182-7. doi: 10.1016/j.mehy.2004.09.026.
10
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.在接受曲妥珠单抗联合化疗的HER-2过表达晚期乳腺癌患者中逆转雌激素受体阴性表型。
Breast Cancer Res. 2006;8(1):R4. doi: 10.1186/bcr1366. Epub 2005 Dec 7.
引用本文的文献
1
Study of Drug Targets Associated With Oncogenesis and Cancer Cell Survival and the Therapeutic Activity of Engineered Ashwagandha Extract Having Differential Withanolide Constitutions.与肿瘤发生和癌细胞存活相关的药物靶点研究以及具有不同醉茄内酯成分的工程化印度人参提取物的治疗活性
Integr Cancer Ther. 2024 Jan-Dec;23:15347354231223499. doi: 10.1177/15347354231223499.
2
Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer.雌激素受体丝氨酸 305 磷酸化如何调节乳腺癌中他莫昔芬的活性的深入了解。
Mol Cell Endocrinol. 2019 Mar 1;483:97-101. doi: 10.1016/j.mce.2019.01.014. Epub 2019 Jan 16.
3
Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.在一项乳腺癌机会性试验中，他汀类药物通过细胞周期蛋白D1和p27诱导抗增殖作用。
J Transl Med. 2015 Apr 29;13:133. doi: 10.1186/s12967-015-0486-0.
4
Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.人乳腺癌细胞中的表皮生长因子受体信号传导与雌激素受体α信号传导平行发挥作用，并导致对他莫昔芬不敏感的增殖。
BMC Cancer. 2014 Apr 23;14:283. doi: 10.1186/1471-2407-14-283.
5
Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer.TANK 结合激酶 1 的高表达增强了乳腺癌对他莫昔芬的耐药性。
Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):E601-10. doi: 10.1073/pnas.1316255111. Epub 2014 Jan 21.
6
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.患者间和患者内（部位间）的雌激素受体结合的变异性，通过 18F-氟雌二醇 PET 进行体内测量。
J Nucl Med. 2011 Oct;52(10):1541-9. doi: 10.2967/jnumed.111.091439. Epub 2011 Sep 8.
7
Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.通过对雌激素受体 α 的作用导致 Rho GDIα 丢失和对他莫昔芬耐药。
J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.
8
Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.DNA 修复途径基因的遗传变异综合筛查与绝经后乳腺癌风险
Breast Cancer Res Treat. 2011 Jan;125(1):207-14. doi: 10.1007/s10549-010-0947-3. Epub 2010 May 23.
9
Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix.雌二醇诱导的T47D:A18/PKCalpha肿瘤消退需要雌激素受体以及与细胞外基质的相互作用。
Mol Cancer Res. 2009 Apr;7(4):498-510. doi: 10.1158/1541-7786.MCR-08-0415.
10
Femara and the future: tailoring treatment and combination therapies with Femara.来曲唑与未来：来曲唑的治疗方案定制及联合疗法
Breast Cancer Res Treat. 2007;105 Suppl 1(Suppl 1):105-15. doi: 10.1007/s10549-007-9697-2. Epub 2007 Oct 3.
本文引用的文献
1
Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.他莫昔芬对人乳腺肿瘤中Ki67标记指数的影响及其与雌激素和孕激素受体状态的关系。
Br J Cancer. 1993 Mar;67(3):606-11. doi: 10.1038/bjc.1993.111.
2
3
4
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.新型纯抗雌激素药物（ICI 182780）用于原发性乳腺癌女性患者的研究。
Cancer Res. 1994 Jan 15;54(2):408-14.
5
Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism.
J Steroid Biochem Mol Biol. 1993 Dec;47(1-6):83-9. doi: 10.1016/0960-0760(93)90060-a.
6
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.接受他莫昔芬治疗的乳腺癌患者体内甾体激素受体的测定。
Breast Cancer Res Treat. 1993;26(3):237-46. doi: 10.1007/BF00665801.
7
Molecular mechanisms of resistance to tamoxifen therapy in breast cancer.乳腺癌中对他莫昔芬治疗耐药的分子机制。
Arch Surg. 1993 Nov;128(11):1187-91. doi: 10.1001/archsurg.1993.01420230015002.
8
Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer.
Br J Cancer. 1994 Jun;69(6):1032-7. doi: 10.1038/bjc.1994.203.
9
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.他莫昔芬代谢在他莫昔芬刺激的乳腺肿瘤生长中的重要性。
Cancer Chemother Pharmacol. 1994;34(2):89-95. doi: 10.1007/BF00685924.
10
Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.乳腺导管原位癌中雌激素受体的表达：与DNA流式细胞术分析及c-erbB-2癌蛋白表达的关系。
Br J Cancer. 1993 Jul;68(1):156-61. doi: 10.1038/bjc.1993.305.
Zotero 插件